trending Market Intelligence /marketintelligence/en/news-insights/trending/qieldp1a8djpo0yqgk8-ga2 content esgSubNav
In This List

Paratek's application for broad-spectrum antibiotic Nuzyra accepted by EMA

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Paratek's application for broad-spectrum antibiotic Nuzyra accepted by EMA

The European Medicines Agency has accepted a marketing authorization application for Paratek Pharmaceuticals Inc.'s Nuzyra to treat a type of bacterial pneumonia and a certain skin infection.

Nuzyra, or omadacycline, was approved by the U.S. Food and Drug Administration earlier in October to treat adult patients with community-acquired bacterial pneumonia and acute skin and skin structure infections.

The marketing authorization application is supported by multiple phase 3 studies for Nuzyra, which show that the drug meets all endpoint requirements of EMA.